London Daily

Focus on the big picture.
Tuesday, Sep 09, 2025

Pfizer-BioNTech Covid-19 jab first to seek roll-out approval in Hong Kong

Pfizer-BioNTech Covid-19 jab first to seek roll-out approval in Hong Kong

A government panel is expected to decide as early as Monday whether to recommend the US-German jab.

The Pfizer-BioNTech Covid-19 vaccine developed by the US and Germany has become the first to apply for an emergency roll-out in Hong Kong and a government advisory panel is expected to decide as early as Monday whether to recommend its use amid confusion over the efficacy of the jab from China’s Sinovac.

In an interview with the Post, experts on the panel would not jump to any conclusion on reports from Brazilian clinical trials that CoronaVac, developed by Sinovac, was just over 50 per cent effective – far less than previously suggested– citing a lack of comprehensive data.

But the panel pledged to be transparent on decisions regarding vaccine applications and all evaluation reports would be made public.

Hong Kong aims to roll out the inoculation programme after the Lunar New Year holiday in mid-February and high-risk groups such as the elderly and health care workers will be given priority for vaccination.

“The application [for the Pfizer-BioNTech vaccine] was submitted in early January. The other two haven’t submitted applications yet,” Professor Wallace Lau Chak-sing, convenor of the Advisory Panel on Covid-19 Vaccines, said on Wednesday. “If the safety level is higher than the risks … we will advise the health minister, who will decide whether to use the vaccine.”

Hong Kong has reached purchase agreements for three vaccines, procuring 7.5 million doses of each. Aside from the Pfizer-BioNTech jabs, supplied by Fosun Pharma, the city has also procured Beijing-based Sinovac’s vaccine and one jointly developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University.

Originally, CoronaVac was expected to arrive in the city this month, followed by Pfizer-BioNTech shots in the first quarter and the AstraZeneca vaccine in the middle of the year.

After procurement, the manufacturers must apply to the government for approval for emergency use in Hong Kong, which is subject to vetting and recommendations by the expert panel. The government-appointed panel then advises health minister Professor Sophia Chan Siu-chee on whether to use it.

Frank Chan Ling-fung, an assistant director of health responsible for drug regulatory affairs, said Fosun had already submitted “hundreds of pages” of documents for the application.

He said a decision could be made in a meeting on Monday at the earliest.

Panel member Professor David Hui Shu-cheong said it was “very likely” the approval process could be completed within a month if data submitted by the vaccine manufacturers was complete and met local regulatory requirements.


Professors Wallace Lau (left) and David Hui


The release on Tuesday of a much lower-than-expected efficacy rate for CoronaVac by a São Paulo-based research institute sparked concerns over the effectiveness of the mainland vaccine.

The Butantan Institute listed the efficacy rate of its phase 3 clinical trials as 50.4 per cent compared with the 78 per cent announced last week.

Lau said the panel was still awaiting the complete clinical trial data. He said experts also needed to review any side effects, evidence of approval by drug regulatory bodies outside Hong Kong and other data supporting the safety and efficacy of a vaccine.

“It is a bit dangerous if we make a conclusion just by looking at one part of the data. It is something we should not do,” he said.

While the figure was just above the minimum efficacy rate of 50 per cent required by the World Health Organization, Hui said more information was needed for a proper interpretation.

The experts said they were still unclear about details of the trial and how the efficacy rate was derived.

“Information such as the age range of participants … whether they counted both symptomatic and asymptomatic patients, distribution of men and women, and whether there were any people with chronic illnesses, and the incidence rate of each side effect. All of these haven’t been provided yet,” Hui said, adding such information would help determine the vaccine’s effectiveness.

He suggested the release of various findings from different trials carried out in Indonesia, Turkey and Brazil had created confusion.

“They should do a summary analysis before releasing the data, rather than publishing data of each country one by one,” he said, adding the figures for the Sinovac vaccine were not reliable enough yet.

William Chui Chun-ming, president of the Society of Hospital Pharmacists of Hong Kong, said Sinovac was less transparent in releasing vaccine information than firms such as AstraZeneca and Pfizer, as no peer-reviewed academic papers had been made available yet.

“Other drug makers will usually release journal articles around the same time as revealing the efficacy figures to the media,” he said.

Lau said evaluation reports on vaccines submitted to the health minister would be made public: “We hope to be most transparent, and to let others know the evidence supporting [our decision].”

That was the practice in countries such as the United States and Britain, where details of vaccine approvals were uploaded online for public access.


The latest data on the CoronaVac has created confusion


On monitoring possible serious side effects, Lau said drug makers would be required to inform Hong Kong of any adverse responses linked to the vaccines overseas. An electronic monitoring system, jointly operated by the Department of Health and University of Hong Kong, would also be in place to gather such information.

The elderly and those with chronic diseases would be identified for extra surveillance on side effects.

Common side effects of the three vaccines procured by Hong Kong include headaches, fever and tiredness. Transverse myelitis, a type of inflammation of the spinal cord, was also reported among some participants in the AstraZeneca-Oxford vaccine trials.

The Food and Health Bureau said it had noted the results of the trials of the Sinovac vaccine conducted in Brazil and the Department of Health had contacted the firm to follow up on obtaining the clinical data for assessment.

Meanwhile, Elderly Services Association of Hong Kong chairman Kenneth Chan Chi-yuk said vaccinations for about 100,000 care home residents and workers were expected to start after the Lunar New Year. Outreach teams from public hospitals would be deployed to such facilities, Chan said after a meeting between government representatives and the sector.

As for elderly residents who might not be intellectually capable of determining whether to get vaccinated and had no family members around, the sector would discuss with the government whether to authorise social workers or caretakers to make the decision.

Newsletter

Related Articles

0:00
0:00
Close
Court Staff Cover Up Banksy Image of Judge Beating a Protester
Social Media Access Curtailed in Turkey After CHP Calls for Rallies Following Police Blockade of Istanbul Headquarters
Nayib Bukele Points Out Belgian Hypocrisy as Brussels Considers Sending Army into the Streets
Elon Musk Poised to Become First Trillionaire Under Ambitious Tesla Pay Plan
France, at an Impasse, Heads Toward Another Government Collapse
Burning the Minister’s House Helped Protesters to Win Justice: Prabowo Fires Finance Minister in Wake of Indonesia Protests
Brazil Braces for Fallout from Bolsonaro Trial by corrupted judge
The Country That Got Too Rich? Public Spending Dominates Norway Election
Nearly 40 Years Later: Nike Changes the Legendary Slogan Just Do It
Generations Born After 1939 Unlikely to Reach Age One Hundred, New Study Finds
End to a four-year manhunt in New Zealand: the father who abducted his children to the forests was killed, the three siblings were found
Germany Suspends Debt Rules, Funnels €500 Billion Toward Military and Proxy War Strategy
EU Prepares for War
BMW Eyes Growth in China with New All‑Electric Neue Klasse Lineup
Trump Threatens Retaliatory Tariffs After EU Imposes €2.95 Billion Fine on Google
Tesla Board Proposes Unprecedented One-Trillion-Dollar Performance Package for Elon Musk
US Justice Department Launches Criminal Mortgage-Fraud Probe into Federal Reserve Governor Lisa Cook
Escalating Drug Trafficking and Violence in Latin America: A Growing Crisis
US and Taiwanese Defence Officials Held Secret Talks in Alaska
Report: Secret SEAL Team 6 Mission in North Korea Ordered by Trump in 2019 Ended in Failure
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Florida Murder Case: The Adelson Family, the Killing of Dan Markel, and the Trial of Donna Adelson
Trump Administration Advances Plans to Rebrand Pentagon as Department of War Instead of the Fake Term Department of Defense
Big Tech Executives Laud Trump at White House Dinner, Unveil Massive U.S. Investments
Tether Expands into Gold Sector with Profit-Driven Diversification
‘Looks Like a Wig’: Online Users Express Concern Over Kate Middleton
Brand-New $1 Million Yacht Sinks Just Fifteen Minutes After Maiden Launch in Turkey
Here’s What the FBI Seized in John Bolton Raid — and the Legal Risks He Faces
Florida’s Vaccine Revolution: DeSantis Declares War on Mandates
Trump’s New War – and the ‘Drug Tyrant’ Fearing Invasion: ‘1,200 Missiles Aimed at Us’
"The Situation Has Never Been This Bad": The Fall of PepsiCo
At the Parade in China: Laser Weapons, 'Eagle Strike,' and a Missile Capable of 'Striking Anywhere in the World'
The Fashion Designer Who Became an Italian Symbol: Giorgio Armani Has Died at 91
Putin Celebrates ‘Unprecedentedly High’ Ties with China as Gazprom Seals Power of Siberia-2 Deal
China Unveils New Weapons in Grand Military Parade as Xi Hosts Putin and Kim
Queen Camilla’s Teenage Courage: Fended Off Attempted Assault on London Train, New Biography Reveals
Scottish Brothers Set Record in Historic Pacific Row
Rapper Cardi B Cleared of Liability in Los Angeles Civil Assault Trial
Google Avoids Break-Up in U.S. Antitrust Case as Stocks Rise
Couple celebrates 80th wedding anniversary at assisted living facility in Lancaster
Information Warfare in the Age of AI: How Language Models Become Targets and Tools
The White House on LinkedIn Has Changed Their Profile Picture to Donald Trump
"Insulted the Prophet Muhammad": Woman Burned Alive by Angry Mob in Niger State, Nigeria
Trump Responds to Death Rumors – Announces 'Missile City'
Court of Appeal Allows Asylum Seekers to Remain at Essex Hotel Amid Local Tax Boycott Threats
Germany in Turmoil: Ukrainian Teenage Girl Pushed to Death by Illegal Iraqi Migrant
United Krack down on human rights: Graham Linehan Arrested at Heathrow Over Three X Posts, Hospitalised, Released on Bail with Posting Ban
Asian and Middle Eastern Investors Avoid US Markets
Ray Dalio Warns of US Shift to Autocracy
×